Boston Strategics Corporation Enters Into An Innovative Risk-Sharing Agreement With MD Anderson Cancer Center To Conduct A Phase 1/2a Clinical Trial Of E6201 In Patients With Advanced Hematologic Malignancies Including Acute Myeloid Leukemia

BOSTON--(BUSINESS WIRE)--Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into a risk-sharing agreement with the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a Phase 1/2a clinical trial of E6201 in patients with advanced hematologic malignancies, including acute myeloid leukemia (AML).

Help employers find you! Check out all the jobs and post your resume.